The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells
Marina Vilaseca, Héctor García‐Calderó, Erica Lafoz, Oihane García‐Irigoyen, Matías A. Avila, Joan Carles Reverter, Jaume Bosch, Virginia Hernández‐Gea, Jordi Gracia‐Sancho, Joan Carles García‐Pagán – 31 January 2017 – In cirrhosis, increased intrahepatic vascular resistance (IHVR) is the primary factor for portal hypertension (PH) development. Hepatic stellate cells (HSCs) play a major role increasing IHVR because, when activated, they are contractile and promote fibrogenesis.